The Commission approved the acquisition of Bausch & Lomb Holdings Inc. (“Bausch & Lomb”), a US based global eye health company, by Valeant Pharmaceuticals International Inc., of Canada. Both parties are active in the markets for ophthalmic pharmaceuticals, consumer vision products and ophthalmic medical products. The Commission’s investigation revealed that the overlaps in consumer vision and ophthalmic medical product segments are very limited. Further, the Commission found that in ophthalmic pharmaceuticals the parties’ products were not close substitutes and that a number of strong competitors would remain in the market after the transaction. Therefore, the Commission concluded that the acquisition would not significantly impede effective competition in the EEA or any substantial part thereof. Source: Commission Press Release 06/08/2013